Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors

NCT04083599 is registered in ClinicalTrials.gov with Genmab as lead sponsor.

NCT NCT04083599
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04083599 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors
Lead sponsor
Genmab
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 17, 2019
Completion date
January 31, 2027
Enrollment
350 (actual)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer (crc), head and neck squamous cell carcinoma (hnscc), malignant solid tumor, melanoma, non-small cell lung cancer (nsclc), pancreatic ductal adenocarcinoma (pdac)